Table E-1: Linkage Studies Using Short-Tandem-Repeat Markers in Families with Presumably

Table e-1: Linkage studies using short-tandem-repeat markers in families with presumably monogenic ET e-1.1 Locus ETM1 Chromosome 3q13 Locus Study Ref. Country Nr. of Fam. Nr. of Pat. Locus excl. Remarks prov. Gulcher 1 ISL 16 2 - 9 no no max. LOD in one family = 1.29 et al. 1997 Illarioshkin TJK 2 5 6/4/2/4/3 no yes, only family 1 et al. 2000 Kovach 3 USA 1 16 no yes et al. 2001 Abbruzzese 4 ITA 6 NS no NS "negative results for all recombination values" et al. 2001 Ma 5 USA 4 19/14/13/19 no no all LODs negative et al. 2006 Lorenz 6 FRA/GER 15 3-15 no yes, in 5 families locus excluded by haplotype reconstruction in all families et al. 2008 Aridon 7 ITA 1 9 no yes et al. 2008 Novelletto 8 ITA 4 6/8/8/6 no no et al. 2011 Pasini 9 ITA 1 5 no yes et al. 2012 e-1.2 Locus ETM2 Chromosome 2p24 Locus Study Ref. Country Nr. of Fam. Nr. of Pat. Locus excl. Remarks prov. Higgins 10 USA 18 4 yes NA max. LOD = 5.92 et al. 1997 Higgins max. LOD = 1.34 in one family, one family reported previously (Higgins 11 USA 14/7/4 3/3/2 no no et al. 1998 1997) not included. Kovach 3 USA 16 3 no no max. LOD = 0.54, most STR with LOD < -2 et al. 2001 Abbruzzese 4 ITA NS NS no NS "negative results for all recombination values" et al. 2001 Ma 5 USA 19/14/13/19 2/2/3/3 no yes max. LOD = -2.66 et al. 2006 Lorenz 6 FRA/GER 3-15 1-3 no NS "locus excluded by haplotype reconstruction in all families" 1 et al. 2008 Aridon 7 ITA 9 2 no (yes) max. LOD D2S220 = -1.70 et al. 2008 Novelletto 8 ITA 6/8/8/6 3/2/2/2 no yes et al. 2011 Pasini 9 ITA 5 3 no yes max. LOD = -3.2 et al. 2012 e-1.3 Locus ETM3 Chromosome 6p23 Study Ref. Country Nr. of Fam. Nr. of Pat. Locus p/c Locus excl. Remarks Shatunov 12 USA 2 14/8 no no max. parametric LOD = 2,93 but "affected only" analysis et al. 2008 Lorenz 6 FRA/GER 15 3-15 no NS "locus excluded by haplotype reconstruction in all families" et al. 2008 Aridon 7 ITA 1 9 no yes et al. 2008 Novelletto 8 ITA 4 6/8/8/6 no yes, in 2 families et al. 2011 Pasini Max. LOD = -0.145 for D6S422, D6S289 = -2.700, 9 ITA 1 5 no no et al. 2012 D6S1678 = -2.882Table e-1: Study – first author and year; Ref. – reference in the supplemental references; Country – 3 letter code of the country of origin; Nr. of Fam. – number of families investigated; Nr. of Pat. – Nr. of ET patients investigated per family; Locus p/c – locus proven if LOD >3.3 in a single family in the initial study or LOD > 2.0 in a replication study of a locus for which LOD > 3.3 in a single family was reached in the initial study.; Locus excl. – locus excluded, if LOD > -2 (at tau = 0) for all markers in the region. NS – not stated, NA – not applicable.2 Table e-2: Co-segregation of candidate gene alleles for ETM-loci with ET in families with presumably monogenic ET e-2.1 Dopamine receptor D3 (DRD3) Study Ref. Poly. Country Nr. of Fam. Nr. of Pat. Gly co-seg. Jeanneteau 13 rs6280 (Ser9Gly) FRA 30 1-5 23/30 et al. 2006 Tan 14 rs6280 (Ser9Gly) SGP 16 NS (42 in all families) 4/16 et al. 2007 Lorenz 6 rs6280 (Ser9Gly) FRA/GER 22 3-16 4/22 et al. 2008 Blair 15 rs6280 (Ser9Gly) USA 8 >10 0/8 et al. 2008 e-2.2 HSCL1 binding protein 3 (HS1BP3) Study Ref. Poly. Country Families Affected Gly co-seg. Higgins 16 Ala265Gly (not in dbSNP) USA 2 10/2 2/2 et al. 2005 Shatunov 17 Ala265Gly (not in dbSNP) USA 2 14/NS 0/2 et al. 2005Table e-2: Study – first author and year; Ref. – reference in the supplemental references; Poly – Polymorphism(s) studied; Country – 3 letter code of the country of origin; Nr. of Fam. – number of families investigated; Nr. of Pat. – Nr. of patients investigated per family; Co-Seg. – co-segregation of minor allele in number of families. NS – not stated, NA – not applicable.3 Table e-3: Mutations in the fused in sarcoma (FUS) gene e-3 Fused in sarcoma (FUS) mutation analysis Study Ref. Country Ca. Co. Mutations/SNPs Mut. Ca. Mut. Co. Remarks Merner 18 FRA/CAN 23 (7 def., 3 prob.,13 poss.) 450 c.868C>T, p.Gln290* 18/23 0/450 5 possible ET without mutation et al. 2012 Merner 1/450 18 FRA/CAN 270 single patients 450 "1 x p.Arg216Cys; 1 x p.Pro431Leu" 2/270 et al. 2012 (p.Arg216Cys) Parmalee in addition no association between 19 USA 116 single patients 262 none 0/116 0/116 et al. 2012 FUS SNPs and ET Zheng in addition no association between 20 CHN 180 single patients 273 1 x p.M392I 1/180 0/273 et al. 2013 FUS SNPs and ET Labbe 21 USA "152 ""familial probands""" NS none 0/152 NS et al. 2013 Rajput only mutation Only the p.R377W mutation and 1 22 CAN 216 single patients 219 1 x p.R377W 1/216 et al. 2013 followed up polymorphism followed in controls. Hedera 23 USA 104 from 52 families 0 none 0/52 families NA et al. 2013 Ortega- Cubero et 24 ESP 178 0 none 0/178 NA 1 intronic base change al. 20134 Table e-4: Association and mutation analysis studies in sporadic ET patients e-4.1 SNPs derived from Genome Wide Association Studies e.4.1.1 Leucine rich repeat and Ig domain containing 1 (LINGO1) Study Ref. Poly. Cou. Ca. Co. CaMi CaMa CoMi CoMa p-val. OR (95% CI) Remarks Stefansson 25 rs9652490 ISL 452 14378 297 607 6614 22142 0.000 1.64 (1.42 - 1.89) GWA discovery sample et al. 2009 Stefansson 25 rs9652490 AUT 77 342 45 109 132 552 0.009 1.73 (1.16 - 2.56) GWA replication sample et al. 2009 Stefansson 25 rs9652490 DEU 69 176 41 97 82 270 0.164 1.39 (0.90 - 2.16) GWA replication sample et al. 2009 Stefansson 25 rs9652490 USA 119 611 65 173 271 951 0.092 1.32 (0.96 - 1.81) GWA replication sample et al. 2009 Stefansson 25 rs9652490 ISL 35 290 19 51 130 450 0.369 1.29 (0.74 - 2.26) GWA replication sample et al. 2009 Tan 26 rs9652490 SGP 190 734 100 280 321 1147 0.001 1.65 (1.24 - 2.19) et al. 2009 Thier 27 rs9652490 DEU 284 334 136 432 107 561 0.045 1.71 (1.02 - 2.86) et al. 2010 Thier 27 rs9652490 FRA 48 240 25 71 82 398 0.074 1.28 (0.98 - 1.65) et al. 2010 Clark 28 rs9652490 USA 257 265 124 390 102 428 0.060 1.33 (0.99 - 1.79) et al. 2010 Zuo 29 rs9652490 CHN 106 410 45 167 177 643 1.000 0.98 (0.68 - 1.42) et al. 2010 Vilarino-Guell 30 rs9652490 USA 353 399 152 554 203 595 0.364 0.87 (0.66 - 1.16) et al. 2010 Vilarino-Guell 123 31 rs9652490 USA 629 570 1902 304 954 0.078 0.80 (0.63 - 1.02) et al. 2010 6 Lorenzo-Betancor 32 rs9652490 ESP 220 1100 67 373 376 1824 0.462 0.94 (0.80 - 1.10) et al. 2011 Wu 33 rs9652490 CHN 117 160 59 175 83 237 0.922 0.96 (0.65 - 1.42) et al. 2011 Bourassa 34 rs9652490 CAN 257 470 114 400 206 734 0.947 1.02 (0.78 - 1.32) et al. 2011 Radovica 35 rs9652490 LVA 141 130 56 226 51 209 1.000 1.02 (0.66- 1.55)5 et al. 2012 LINGO1 Study Ref. Poly. Cou. Ca. Co. CaMi CaMa CoMi CoMa p-val. OR (95% CI) Remarks Stefansson 1012 25 rs11856808 ISL 451 14385 407 495 18643 0.000 1.51 (1.32 - 1.73) et al. 2009 7 Stefansson 25 rs11856808 AUT 77 341 66 90 228 454 0.041 1.46 (1.02 - 2.08) et al. 2009 Stefansson 25 rs11856808 DEU 69 173 51 87 116 230 0.525 1.16 (0.77 - 1.75) et al. 2009 Stefansson 25 rs11856808 USA 120 611 89 151 437 785 0.713 1.06 (0.79 - 1.41) et al. 2009 Stefansson 25 rs11856808 ISL 35 283 28 42 178 388 0.175 1.45 (0.87 - 2.42) et al. 2009 Thier 27 rs11856808 DEU 284 334 187 381 187 481 0.063 1.26 (0.99 - 1.61) et al. 2010 Thier 27 rs11856808 FRA 48 240 40 56 144 336 0.031 1.67 (1.06 - 2.61) et al. 2010 Clark 28 rs11856808 USA 257 265 209 305 195 335 0.204 1.18 (0.92 - 1.51) et al. 2010 Zuo 29 rs11856808 CHN 106 310 71 141 272 348 0.010 0.64 (0.46 - 0.89) et al. 20106 Lorenzo-Betancor 32 rs11856808 ESP 224 1076 124 324 672 1480 0.143 0.84 (0.67 - 1.06) et al. 2011 Bourassa 34 rs11856808 CAN 251 471 163 339 330 612 0.351 0.89 (0.71 - 1.12) et al. 2011 Radovica 35 rs11856808 LVA 141 130 84 198 79 181 0.925 0.97 (0.67 - 1.40) et al. 2012 e-4.1.2 Solute carrier family 1 member 2 (SLC1A2) Study Ref. Poly. Cou. Ca. Co. CaMi CaMa CoMi CoMa p-val. OR (95% CI) Remarks DEU Thier 36 rs3794087 AUT 410 919 235 585 395 1443 0.000 1.47 (1.21 - 1.78) GWA discovery sample et al. 2012 DEN DEU Thier 36 rs3794087 AUT 496 571 290 702 264 878 0.002 1.37 (1.13 - 1.68) GWA replication sample et al. 2012 DEN Tan Reported as association with the major 37 rs3794087 CHN 357 1935 110 604 741 3129 0.018 0.77 (0.61 - 0.96) et al. 2013 allele Yu 38 rs3794087 TWN 273 269 123 423 94 444 0.040 1.37 (1.007-1.87) et al. 2013 Garcia-Martin 39 rs3794087 ESP 202 308 87 317 154 462 0.228 0.82 (0.60-1.12) et al. 2013 e-4.2 Candidate Gene Association Studies e-4.2.1 Candidate genes in ETM1 and -2 linkage regions e-4.2.1.1 ETM1: Dopamine Receptor 3 (rs6280) Study Ref. Poly. Cou. Ca. Co. CaMi CaMa CoMi CoMa p-val. OR (95% CI) Remarks Jeanneteau rs6280 13 USA 276 184 187 365 101 267 0.042 1.35 (1.00 - 1.83) et al. 2006 (Ser9Gly) Tan rs6280 14 SNG 163 192 106 220 127 257 0.936 0.98 (0.70 - 1.35) et al. 2007 (Ser9Gly) FRA Lorenz rs6280 6 DEU 299 528 200 398 334 722 0.477 1.09 (0.87 - 1.35) et al. 2008 (Ser9Gly) DEN Vitale rs6280 40 ITA 116 158 87 145 141 175 0.097 0.75 (0.52-1.07) et al. 2008 (Ser9Gly) Blair rs6280 15 USA 237 272 179 295 215 329 0.606 0.93 (0.72 - 1.21) et al. 2008 (Ser9Gly)7 Inashkina rs6280 41 LVA 104 116 55 153 56 176 0.590 1.13 (0.72-1.78) + 7 STR association study, also negative et al. 2008 (Ser9Gly) Garcia-Martin rs6280 42 ESP 201 282 128 274 134 430 0.007 1.50 (1.12 - 2.02) et al. 2009 (Ser9Gly) e-4.2.1.2 ETM2: HS1BP3 Ala265Gly (not in dbSNP) Study Ref. Poly. Cou. Ca. Co. CaMi CaMa CoMi CoMa p-val. OR (95% CI) Remarks Deng 43 Ala265Gly USA 222 132 20 424 12 252 1.000 0.99 (0.45-2.19) familial ET et al. 2005 NA (because Higgins “singletons representing dominantly 44 Ala265Gly USA 73 304 12 134 0 608 0.000 allele not present et al. 2006 inherited ET” in controls) e-4.2.2 Gamma amino butyric acid (GABA) system Study Ref. Poly. Cou. Ca. Co. CaMi CaMa CoMi CoMa p-val. OR (95% CI) Remarks Sequencing of GABRA1 gene. No Deng Too many to 45 USA 197 114 NA NA NA NA NA NA mutations/polymorphisms associated with et al. 2006 report. ET. Four missense SNPs in GABA-related Garcia-Martin Too many to 46 ESP 200 250 NA NA NA NA NA NA genes. No association between SNPs and et al. 2011 report. ET. Three missense SNPs in GABA-related Garcia-Martin Too many to 47 ESP 200 250 NA NA NA NA NA NA genes. No association between SNPs and et al. 2011 report. ET.8 240 tagging SNPs cov. GABA-related Thier Too many to genes. 9 nominally significant in discovery 48 DEU 503 818 NA NA NA NA NA NA et al. 2011 report. sample but not replicated in verification sample. e-4.2.3 Genes associated with PD Alpha-Synuclein (SNCA) Study Ref. Poly. Cou. Ca. Co. CaMi CaMa CoMi CoMa p-val. OR (95% CI) Remarks Tan Association between NACP-Rep1 length 49 NACP-Rep1 USA 46 100 NA NA NA NA NA NA et al. 2000 and ET . Pigullo NACP-Rep1 NACP-Rep1 and five SNPs not associated 50 ITA 106 90 NA NA NA NA NA NA et al. 2003 and 5 SNPs with ET. Ross No association between 20 SNPs in the 51 20SNPs USA 661 1316 NA NA NA NA NA NA et al. 2011 SNCA gene and ET Micotubule associated protein tau (MAPT) Study Ref. Poly. Cou. Ca. Co. CaMi CaMa CoMi CoMa p-val. OR (95% CI) Remarks Vilarino-Guell rs1052553 discriminates the MAPT-H1 52 rs1052553 USA 356 409 136 542 202 610 0.030 0.76 (0.59 - 0.98) et al. 2011 haplotype Garcia-Martin rs1052553 discriminates the MAPT-H1 53 rs1052553 ESP 20 291 253 825 357 1037 0.240 0.89 (0.74 - 1.08) et al. 2012 haplotype, “familial cases” Parkin Study Ref. Poly. Cou. Ca. Co. CaMi CaMa CoMi CoMa p-val. OR (95% CI) Remarks Pigullo No putatively causal mutations in Parkin in 54 NA ITA 110 none NA NA NA NA NA NA et al. 2004 ET patients. Leucine rich repeat kinase 2 (LRRK2) Study Ref. Poly. Cou. Ca. Co. CaMi CaMa CoMi CoMa p-val. OR (95% CI) Remarks G2019S, Deng 55 I2012T, USA 272 none NA NA NA NA NA NA No mutations found. et al. 2006 I2020T9 Tan Found in 4% of ET and 2,9% of control 56 G2385R SNG 172 247 NA NA NA NA NA NA et al. 2008 individuals: no association with ET. Vitale DNA seq. of Sequencing of LRRK2 exon 41. No novel or 57 ITA 116 none NA NA NA NA NA NA et al. 2009 Exon 41 known mutations detected. No association with ET. G2019S, I2020T, Clark 58 See remarks USA 275 289 NA NA NA NA NA NA R1441C, Y1699C, L1114L, I1122V + 19 et al. 2010 additional SNPs Glucocerebrosidase gene (GBA) Study Ref. Poly. Cou. Ca. Co. CaMi CaMa CoMi CoMa p-val. OR (95% CI) Remarks Sun rs35095275 59 CHN 109 none NA NA NA NA NA NA No mutation L444P found in ET patients. et al. 2012 (L444P) Clark DNA seq. of No association of GBA mutations with ET 58 USA 93 62 NA NA NA NA NA NA et al. 2010 GBA (Ashkenazim) e-4.2.4 Genes associated with repeat expansion disorders Fragile X mental retardation protein (FMR1) Study Ref. Poly. Cou. Ca. Co. CaMi CaMa CoMi CoMa p-val. OR (95% CI) Remarks Tan FMR1 not expanded to 60 FMR1 rep. SNG 167 200 NA NA NA NA NA NA et al. 2004 premutation/mutation alleles in ET. Deng FMR1 not expanded to 61 FMR1 rep. USA 196 none NA NA NA NA NA NA et al. 2004 premutation/mutation alleles in ET. Garcia Arocena FMR1 not expanded to 62 FMR1 rep. USA 81 none NA NA NA NA NA NA et al. 2004 premutation/mutation alleles in ET. C9 open reading frame 72 (C9orf72, causative gene for ALS, FTD) Study Ref. Poly. Cou. Ca. Co. CaMi CaMa CoMi CoMa p-val. OR (95% CI) Remarks Dejesus-Hernandez C9orf72 63 USA 106 1356 NA NA NA NA NA NA (GGGGCC) C9orf72 rep. not altered in ET et al. 2012 (GGGGCC)10 "Ataxin 2 (ATX2); Machado-Joseph-disease 1 (MJD1, causative gene SCA3)" Study Ref. Poly. Cou. Ca. Co. CaMi CaMa CoMi CoMa p-val. OR (95% CI) Remarks Tan ATX2, MJD1 One ET patient with 59 CAG repeats in the 64 SNG 177 none NA NA NA NA NA NA et al. 2007 CAG MJD1 gene. CAG expansion (general: repeat expansion detection = RED method) Study Ref. Poly. Cou. Ca. Co. CaMi CaMa CoMi CoMa p-val. OR (95% CI) Remarks """Repeat Expansion Detection"" (RED) Pigullo 65 NA ITA 98 none NA NA NA NA NA NA detected no significantly expanded CAG in et al. 2001 ET patients." e-4.2.5 Other genes (in alphabetical order) Alcohol dehydrogenase 2 (ADH2) Study Ref. Poly. Cou. Ca. Co. CaMi CaMa CoMi CoMa p-val. OR (95% CI) Remarks Martinez "rs1229984 66 ESP 204 200 21 387 27 373 0.373 0.75 (0.40 - 1.40) et al. 2007 (Arg48His); " Cytochrome alleles (Cyp) Study Ref. Poly. Cou. Ca. Co. CaMi CaMa CoMi CoMa p-val. OR (95% CI) Remarks Agundez 8 CYP2D6 No association between CYP2D6 variants 67 ESP 91 258 NA NA NA NA NA NA et al. 1997 all. and ET. Alonso-Navarro CYP2C19 CYP2C19*2 (p = 0.0067*) higher in ET 68 ESP 200 300 NA NA NA NA NA NA et al. 2006 alleles patients. CYP2C8, Martinez CYP2C8*3 (p = 0.006*), CYP2C9*2 (p = 69 CYP2C9 ESP 200 300 NA NA NA NA NA NA et al. 2007 0.05*) significantly reduced in ET patients. alleles Glutathione S-transferase (GST) Study Ref. Poly. Cou. Ca. Co. CaMi CaMa CoMi CoMa p-val. OR (95% CI) Remarks Martinez rs1695 70 ESP 200 220 126 274 136 304 0.882 1.03 (0.76 - 1.39) et al. 2008 (Ile105Val)11 Histamine N-methyltransferase (HNMT) Study Ref. Poly. Cou. Ca. Co. CaMi CaMa CoMi CoMa p-val. OR (95% CI) Remarks Ledesma rs11558538 71 ESP 204 295 28 380 68 522 0.016 0.57 (0.35 - 0.92) et al. 2008 (T205I) Keeling rs11558538 0.99 (0.702 - 72 USA 338 409 72 604 88 730 1.000 et al. 2010 (T205I) 1.39) LINGO2 Study Ref. Poly. Cou Ca. Co. CaMi CaMa CoMi CoMa p-val. OR (95% CI) Remarks 21 SNPs, rs1412229, p = 0.015 recess. Vilarino-Guell 31 rs1412229 USA 1236 629 NA NA NA NA NA NA model, no mult. testing corr., allele freq. not et al. 2010 given Wu CHN/ 8 SNPs , rs7033345 rep. as p = 0.04 in the 73 rs7033345 327 496 283 371 392 600 0.138 1.17 (0.95 - 1.43) et al. 2011 SGP rec. model, no mult. testing corr. Wu 8 SNPs, rs10812774 rep. as p = 0.01 in the 73 rs10812774 325 497 296 354 438 556 0.578 1.06 (0.87 - 1.30) et al. 2011 rec. model, no mult. test. corr. LINGO4 Study Ref. Poly. Cou Ca. Co. CaMi CaMa CoMi CoMa p-val. OR (95% CI) Remarks Liang 74 rs61746299 CHN 150 300 116 184 232 368 1.00 1.00 (0.75 - 1.34) 2 SNPs + mut. screen of LINGO4 et al. 2012 Liang 74 rs1521179 CHN 150 300 107 193 218 382 0.88 0.97 (0.72 - 1.31) 2 SNPs + mut. screen of LINGO4 et al. 2012 Methylene tetrahydrofolate reductase (MTHFR) Study Ref. Poly. Cou. Ca. Co. CaMi CaMa CoMi CoMa p-val. OR (95% CI) Remarks Sazci rs1801133 75 TUR 158 246 113 203 148 344 0.105 1.29 (0.95 - 1.77) (Ala222Val) et al. 2004 (C677T) Sazci rs1801131 75 TUR 158 246 107 209 130 362 0.027 1.43 (1.04 - 1.96) (Glu429Ala) et al. 2004 (A1298C)12 Paraxoxonase/arylesterase 1 (PON1) Study Ref. Poly. Cou. Ca. Co. CaMi CaMa CoMi CoMa p-val. OR (95% CI) Remarks Garcia-Martin rs854560 76 ESP 201 220 166 236 170 270 0.439 1.12 (0.84 - 1.49) et al. 2010 (Leu55Met) Garcia-Martin rs662 76 ESP 201 220 121 281 133 307 0.439 1.12 (0.84 - 1.49) et al. 2010 (Gln192Arg) Protein phosphatase 2, regulatory subunit beta (PPP2R2B, causative gene SCA12) Study Ref. Poly. Cou. Ca. Co. CaMi CaMa CoMi CoMa p-val. OR (95% CI) Remarks Nicoletti SCA12 CAG 77 ITA 30 none NA NA NA NA NA NA No expanded CAG-repeats et al. 2002 rep. Chen SCA12 CAG 78 TWN 132 none NA NA NA NA NA NA No expanded CAG-repeats et al. 2009 rep. Sodium channel voltage gated type 8 alpha subunit (SCN8A) Study Ref. Poly. Cou. Ca. Co. CaMi CaMa CoMi CoMa p-val. OR (95% CI) Remarks Sharkey No mutations in the SCN8A gene in ET 79 NA USA 95 none NA NA NA NA NA NA et al. 2009 patients.Table e-3: Study – first author and year of study, Ref. – reference in the supplemental references; Poly. – polymorphism(s) studied; Cou. – 3 letter code of the country of origin. Ca. – number of cases; Co. – number of controls; CaMi – minor allele count in cases; CaMa – major allele count in cases; CoMi – minor allele count in controls; CoMa – major allele count in controls; p-val. – allelic p-value calculated using Fisher’s exact test (might be different from the p-value given in the study because of different statistical methods or genetic models (e.g. genotypic/dominant/recessive model in the studies); OR (95% CI) – odds ratio and 95% CI in the allelic model., Remarks – special features and comments.13 Supplemental references:1. Gulcher JR, Jonsson P, Kong A, et al. Mapping of a familial essential tremor gene, FET1, to chromosome 3q13. Nat Genet 1997;17:84-87.2. Illarioshkin SN, Ivanova-Smolenskaya IA, Rahmonov RA, Markova ED, Stevanin G, Brice A. Clinical and genetic study of familial essential tremor in an isolate of Northern Tajikistan. Mov Disord 2000;15:1020-1023.3. Kovach MJ, Ruiz J, Kimonis K, et al. Genetic heterogeneity in autosomal dominant essential tremor. Genet Med 2001;3:197-199.4. Abbruzzese G, Pigullo S, Di Maria E, et al. Clinical and genetic study of essential tremor in the Italian population. Neurol Sci 2001;22:39-40.5. Ma S, Davis TL, Blair MA, et al. Familial essential tremor with apparent autosomal dominant inheritance: should we also consider other inheritance modes? Mov Disord 2006;21:1368-1374.6. Lorenz D, Klebe S, Stevanin G, et al. Dopamine receptor D3 gene and essential tremor in large series of German, Danish and French patients. Eur J Hum Genet 2008;17:766-773.7. Aridon P, Ragonese P, De Fusco M, Salemi G, Casari G, Savettieri G. Further evidence of genetic heterogeneity in familial essential tremor. Parkinsonism Relat Disord 2008;14:15-18.8. Novelletto A, Gulli R, Ciotti P, et al. Linkage exclusion in Italian families with hereditary essential tremor. Eur J Neurol 2011;18:e118-120.9. Pasini E, Busolin G, Nobile C, Michelucci R. Autosomal dominant essential tremor: a novel family with anticipation. Neurol Sci 2012.10. Higgins JJ, Pho LT, Nee LE. A gene (ETM) for essential tremor maps to chromosome 2p22-p25. Mov Disord 1997;12:859-864.11. Higgins JJ, Loveless JM, Jankovic J, Patel PI. Evidence that a gene for essential tremor maps to chromosome 2p in four families. Mov Disord 1998;13:972-977.12. Shatunov A, Sambuughin N, Jankovic J, et al. Genomewide scans in North American families reveal genetic linkage of essential tremor to a region on chromosome 6p23. Brain 2006;129:2318-2331.13. Jeanneteau F, Funalot B, Jankovic J, et al. A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc Natl Acad Sci U S A 2006;103:10753-10758.14. Tan EK, Prakash KM, Fook-Chong S, et al. DRD3 variant and risk of essential tremor. Neurology 2007;68:790-791.14 15. Blair MA, Ma S, Phibbs F, et al. Reappraisal of the role of the DRD3 gene in essential tremor. Parkinsonism Relat Disord 2008;14:471-475.16. Higgins JJ, Lombardi RQ, Pucilowska J, Jankovic J, Tan EK, Rooney JP. A variant in the HS1-BP3 gene is associated with familial essential tremor. Neurology 2005;64:417-421.17. Shatunov A, Jankovic J, Elble R, et al. A variant in the HS1-BP3 gene is associated with familial essential tremor. Neurology 2005;65:1995; author reply 1995.18. Merner ND, Girard SL, Catoire H, et al. Exome Sequencing Identifies FUS Mutations as a Cause of Essential Tremor. Am J Hum Genet 2012;91:313-319.19. Parmalee N, Mirzozoda K, Kisselev S, et al. Genetic analysis of the FUS/TLS gene in essential tremor. Eur J Neurol 2012;20:534-539.20. Zheng W, Deng X, Liang H, et al. Genetic analysis of the fused in sarcoma gene in Chinese Han patients with essential tremor. Neurobiol Aging 2013;34:e3-4.21. Labbe C, Soto-Ortolaza AI, Rayaprolu S, et al. Investigating the role of FUS exonic variants in Essential Tremor. Parkinsonism Relat Disord 2013:[Epub ahead of print].22. Rajput A, Rajput AH, Rajput ML, et al. Identification of FUS p.R377W in essential tremor. Eur J Neurol 2013.23. Hedera P, Davis TL, Phibbs FT, Charles PD, LeDoux MS. FUS in familial essential tremor - the search for common causes is still on. Parkinsonism Relat Disord 2013;19:818-820.24. Ortega-Cubero S, Lorenzo-Betancor O, Lorenzo E, et al. Fused in Sarcoma (FUS) gene mutations are not a frequent cause of essential tremor in Europeans. Neurobiol Aging 2013;34:2441 e2449-2441 e2411.25. Stefansson H, Steinberg S, Petursson H, et al. Variant in the sequence of the LINGO1 gene confers risk of essential tremor. Nat Genet 2009;41:277-279.26. Tan EK, Teo YY, Prakash KM, et al. LINGO1 variant increases risk of familial essential tremor. Neurology 2009;73:1161-1162.27. Thier S, Lorenz D, Nothnagel M, et al. LINGO1 polymorphisms are associated with essential tremor in Europeans. Mov Disord 2010;25:709-715.28. Clark LN, Park N, Kisselev S, Rios E, Lee JH, Louis ED. Replication of the LINGO1 gene association with essential tremor in a North American population. Eur J HumGenet 2010;18:838-843.29. Zuo X, Jiang H, Guo JF, et al. Screening for two SNPs of LINGO1 gene in patients with essential tremor or sporadic Parkinson's disease in Chinese population. Neurosci Lett 2010;481:69-72.15 30. Vilarino-Guell C, Ross OA, Wider C, et al. LINGO1 rs9652490 is associated with essential tremor and Parkinson disease. Parkinsonism Relat Disord 2010;16:109-111.31. Vilarino-Guell C, Wider C, Ross OA, et al. LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. Neurogenetics 2010;11:401-408.32. Lorenzo-Betancor O, Garcia-Martin E, Cervantes S, et al. Lack of association of LINGO1 rs9652490 and rs11856808 SNPs with familial essential tremor. Eur J Neurol 2011;18:1085-1089.33. Wu YW, Rong TY, Li HH, et al. Analysis of Lingo1 variant in sporadic and familial essential tremor among Asians. Acta Neurol Scand 2011;124:264-268.34. Bourassa CV, Riviere JB, Dion PA, et al. LINGO1 Variants in the French-Canadian Population. PLoS One 2011;6:e16254.35. Radovica I, Inashkina I, Smeltere L, Vitols E, Jankevics E. Screening of 10 SNPs of LINGO1 gene in patients with essential tremor in the Latvian population. Parkinsonism Relat Disord 2012;18:93-95.36. Thier S, Lorenz D, Nothnagel M, et al. Polymorphisms in the glial glutamate transporter SLC1A2 are associated with essential tremor. Neurology 2012;79:243-248.37. Tan EK, Foo JN, Tan L, et al. SLC1A2 variant associated with essential tremor but not Parkinson disease in Chinese subjects. Neurology 2013;80:1618-1619.38. Yu SW, Chen CM, Chen YC, et al. SLC1A2 Variant Is Associated with Essential Tremor in Taiwanese Population. PLoS One 2013;8:e71919.39. Garcia-Martin E, Martinez C, Alonso-Navarro H, et al. No association of the SLC1A2 rs3794087 allele with risk for essential tremor in the Spanish population. Pharmacogenet Genomics 2013.40. Vitale C, Gulli R, Ciotti P, et al. DRD3 Ser9Gly variant is not associated with essential tremor in a series of Italian patients. Eur J Neurol 2008;15:985-987.41. Inashkina I, Radovica I, Smeltere L, Vitols E, Jankevics E. Case-control study of patients with essential tremor in Latvia. Eur J Neurol 2008;15:988-990.42. Garcia-Martin E, Martinez C, Alonso-Navarro H, et al. Dopamine receptor D3 (DRD3) genotype and allelic variants and risk for essential tremor. Mov Disord 2009;24:1910-1915.43. Deng H, Le WD, Guo Y, Huang MS, Xie WJ, Jankovic J. Extended study of A265G variant of HS1BP3 in essential tremor and Parkinson disease. Neurology 2005;65:651-652.16 44. Higgins JJ, Lombardi RQ, Pucilowska J, Jankovic J, Golbe LI, Verhagen L. HS1-BP3 gene variant is common in familial essential tremor. Mov Disord 2006;21:306-309.45. Deng H, Xie WJ, Le WD, Huang MS, Jankovic J. Genetic analysis of the GABRA1 gene in patients with essential tremor. Neurosci Lett 2006;401:16-19.46. Garcia-Martin E, Martinez C, Alonso-Navarro H, et al. Gamma-aminobutyric acid GABRA4, GABRE, and GABRQ receptor polymorphisms and risk for essential tremor. Pharmacogenet Genomics 2011;21:436-439.47. Garcia-Martin E, Martinez C, Alonso-Navarro H, et al. Gamma-aminobutyric acid (GABA) receptor rho (GABRR) polymorphisms and risk for essential tremor. J Neurol2011;258:203-211.48. Thier S, Kuhlenbäumer G, Lorenz D, et al. GABAA Receptor- and GABA Transporter Polymorphisms and Risk for Essential Tremor. Eur J Neurol 2011;18:1098-1100.49. Tan EK, Matsuura T, Nagamitsu S, Khajavi M, Jankovic J, Ashizawa T. Polymorphism of NACP-Rep1 in Parkinson's disease: an etiologic link with essential tremor? Neurology 2000;54:1195-1198.50. Pigullo S, Di Maria E, Marchese R, et al. Essential tremor is not associated with alpha-synuclein gene haplotypes. Mov Disord 2003;18:823-826.51. Ross OA, Conneely KN, Wang T, et al. Genetic variants of alpha-synuclein are not associated with essential tremor. Mov Disord 2011;26:2552-2556.52. Vilarino-Guell C, Soto-Ortolaza AI, Rajput A, et al. MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy. Neurology 2011;76:670-672.53. Garcia-Martin E, Martinez C, Alonso-Navarro H, et al. H1-MAPT and the Risk for Familial Essential Tremor. PLoS One 2012;7:e41581.54. Pigullo S, De Luca A, Barone P, et al. Mutational analysis of parkin gene by denaturing high-performance liquid chromatography (DHPLC) in essential tremor. Parkinsonism Relat Disord 2004;10:357-362.55. Deng H, Le W, Davidson AL, Xie W, Jankovic J. The LRRK2 I2012T, G2019S and I2020T mutations are not common in patients with essential tremor. Neurosci Lett 2006;407:97-100.56. Tan EK, Lee J, Lim HQ, Yuen Y, Zhao Y. Essential tremor and the common LRRK2 G2385R variant. Parkinsonism Relat Disord 2008;14:569-571.57. Vitale C, Ciotti P, Gulli R, et al. Common mutations in the LRRK2 exon 41 are not responsible for essential tremor in Italian patients. Parkinsonism Relat Disord 2009;15:162-163.17 58. Clark LN, Kisselev S, Park N, et al. Mutations in the Parkinson's disease genes, Leucine Rich Repeat Kinase 2 (LRRK2) and Glucocerebrosidase (GBA), are not associated with essential tremor. Parkinsonism Relat Disord 2010;16:132-135.59. Sun QY, Guo JF, Han WW, et al. Genetic association study of glucocerebrosidase gene L444P mutation in essential tremor and multiple system atrophy in mainland. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2012.60. Tan EK, Zhao Y, Puong KY, et al. Fragile X premutation alleles in SCA, ET, and parkinsonism in an Asian cohort. Neurology 2004;63:362-363.61. Deng H, Le W, Jankovic J. Premutation alleles associated with Parkinson disease and essential tremor. JAMA 2004;292:1685-1686.62. Garcia Arocena D, Louis ED, Tassone F, et al. Screen for expanded FMR1 alleles in patients with essential tremor. Mov Disord 2004;19:930-933.63. Dejesus-Hernandez M, Rayaprolu S, Soto-Ortolaza AI, et al. Analysis of the C9orf72 repeat in Parkinson's disease, essential tremor and restless legs syndrome. Parkinsonism Relat Disord 2012.64. Tan EK, Tong J, Pavanni R, Wong MC, Zhao Y. Genetic analysis of SCA 2 and 3 repeat expansions in essential tremor and atypical Parkinsonism. Mov Disord 2007;22:1971-1974.65. Pigullo S, Di Maria E, Marchese R, et al. No evidence of association between CAG expansions and essential tremor in a large cohort of Italian patients. J Neural Transm 2001;108:297-304.66. Martinez C, Garcia-Martin E, Alonso-Navarro H, et al. Alcohol dehydrogenase 2 genotype and allelic variants are not associated with the risk for essential tremor. Clinical neuropharmacology 2007;30:196-200.67. Agundez JA, Jimenez-Jimenez FJ, Tejeda R, et al. CYP2D6 polymorphism is not associated with essential tremor. Eur Neurol 1997;38:99-104.68. Alonso-Navarro H, Martinez C, Garcia-Martin E, et al. CYP2C19 polymorphism and risk for essential tremor. Eur Neurol 2006;56:119-123.69. Martinez C, Garcia-Martin E, Alonso-Navarro H, et al. Changes at the CYP2C locus and disruption of CYP2C8/9 linkage disequilibrium in patients with essential tremor. Neuromolecular Med 2007;9:195-204.70. Martinez C, Garcia-Martin E, Alonso-Navarro H, et al. Glutathione-S-transferase P1 polymorphism and risk for essential tremor. Eur J Neurol 2008;15:234-238.18 71. Ledesma MC, Garcia-Martin E, Alonso-Navarro H, et al. The nonsynonymous Thr105Ile polymorphism of the histamine N-methyltransferase is associated to the risk of developing essential tremor. Neuromolecular Med 2008;10:356-361.72. Keeling BH, Vilarino-Guell C, Soto-Ortolaza AI, et al. Histamine N-methyltransferase Thr105Ile is not associated with Parkinson's disease or essential tremor. Parkinsonism Relat Disord 2010;16:112-114.73. Wu YW, Prakash KM, Rong TY, et al. Lingo2 variants associated with essential tremor and Parkinson's disease. Hum Genet 2011;129:611-615.74. Liang H, Zheng W, Xu H, et al. No evidence of association between the LINGO4 gene and essential tremor in Chinese Han patients. Parkinsonism Relat Disord 2012;18:303-305.75. Sazci A, Ergul E, Bayulkem K. Association of the C677T and A1298C polymorphisms of methylenetetrahydrofolate reductase gene in patients with essential tremor in Turkey. Mov Disord 2004;19:1472-1476.76. Garcia-Martin E, Martinez C, Alonso-Navarro H, et al. Paraoxonase 1 (PON1) polymorphisms and risk for essential tremor. Eur J Neurol 2010;17:879-881.77. Nicoletti G, Annesi G, Carrideo S, et al. Familial essential tremor is not associated with SCA-12 mutation in southern Italy. Mov Disord 2002;17:837-838.78. Chen CM, Hou YT, Liu JY, et al. PPP2R2B CAG repeat length in the Han Chinese in Taiwan: Association analyses in neurological and psychiatric disorders and potential functional implications. Am J Med Genet B Neuropsychiatr Genet 2009;150B:124-129.79. Sharkey LM, Jones JM, Hedera P, Meisler MH. Evaluation of SCN8A as a candidate gene for autosomal dominant essential tremor. Parkinsonism Relat Disord 2009;15:321-323.19

Table E-1: Linkage Studies Using Short-Tandem-Repeat Markers in Families with Presumably

Details

Download

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

Support